Clinical trials: Generations
Acute Myeloid Leukemia, Adult
Investigation of the Gut Microbiota in Acute Myeloid Leukemia Receiving Two Different Induction Therapies
In this observational single-center cohort study, metagenomic Next-Generation Sequencing (mNGS) will be used to investigate the features and changes of gut microbiota in acute myeloid leukemia (AML) patients during the treatment…
- Conditions
- Acute Myeloid Leukemia, Adult, Gut Microbiota, Infections
- Trial name
- NCT05123352
- Testing
- collection of biological samples and clinical data
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Neonatal Vitamin A Supplementation
Efficacy of Newborn Vitamin A Supplementation Versus Placebo in Improving Child Survival (NeoVitA Trial)
The study is a large randomized controlled trial to assess the efficacy and safety of neonatal vitamin A supplementation administered to neonates once orally either on the day of birth or in the next 2 days in improving infant…
- Trial name
- NCT01138449
- Testing
- Vitamin A
- Where
- India
- Volunteers
- 44,984 people, healthy volunteers welcome
- Sponsor
- Society for Applied Studies
Non-Small Cell Lung Cancer
Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors
The purpose of this study is to evaluate the safety and effectiveness of this investigational drug, brigatinib (AP261136) in patients with advanced non-small cell lung cancer Non-small cell lung cancer (NSCLC) who have had…
- Trial name
- NCT02706626
- Testing
- brigatinib
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- Criterium, Inc.
Adenocarcinoma of Lung, EGFR Activating Mutation
Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study
The concomitant co-mutation with epidermal growth factor receptor (EGFR) mutation might influence the clinical outcomes. The investigators will identify the impact of concommitant mutation on clinical outcome in patients with…
- Trial name
- NCT04122833
- Testing
- Next generation sequencing
- Where
- 2 sites in South Korea
- Volunteers
- 80 people
- Sponsor
- Konkuk University Medical Center
Coronary Artery Disease (CAD), Stable Angina Pectoris
Identification of Lesion Characteristics in Coronary Plaques Using Multimodality Intravascular Imaging and Novel Photon-counting CT in Stable Angina
Coronary artery disease, caused by the furring up of the heart arteries by atherosclerosis, is a major cause of death in the UK.
- Conditions
- Coronary Artery Disease (CAD), Stable Angina Pectoris, Ischaemic Heart Disease (IHD)
- Trial name
- ILUMINA (NCT07864025)
- Testing
- observational study
- Where
- United Kingdom
- Volunteers
- 70 people
- Sponsor
- Queen Mary University of London
Solid Organ Transplantation, Pregnancy
Long-term Follow-up of the Offspring Born to Mothers With a Solid Organ Transplant, Transplantlines Next Generation
Background Pregnancy after all types of solid organ transplantation (SOT) is possible, although these have higher risk of pregnancy complications for mother and child, such as preeclampsia and preterm birth.
- Conditions
- Solid Organ Transplantation, Pregnancy, Long-term Follow-up, Kidney Transplant
- Trial name
- NCT07291258
- Where
- Netherlands
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University Medical Center Groningen
Solid Carcinoma
Thrombin Generation and Prediction of Thromboembolic Events in Oncology Patients at Risk
Coagulation is a complex system which, through the action of thrombin, leads to the formation of fibrin, which stabilises the platelet clot.
- Trial name
- THROMBIN (NCT06051214)
- Testing
- thrombogram
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Institut Cancerologie de l'Ouest
Ovarian Cancer
The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer
The goal of this clinical trial is to study the safety and feasibility of anti- Mesothelin Chimeric Antigen Receptor T-Cell (MESO CAR-T cells) therapy for Refractory-Relapsed Ovarian Cancer
- Trial name
- NCT03814447
- Testing
- anti- MESO CAR-T cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai 6th People's Hospital
Coronary Artery Disease, Acute Coronary Syndrome
Platelet Acetyl Coenzyme A Carboxylase Phosphorylation in Coronary Artery Disease
In human purified platelets, only thrombin, and not the other platelet agonists, leads to a transient activation of the protein kinase activated by AMP (AMPK) and to phosphorylation of its "bona fide" substrate, ACC on its Ser79.
- Conditions
- Coronary Artery Disease, Acute Coronary Syndrome, Coronary Thrombosis
- Trial name
- ACCTHEROMA (NCT03034148)
- Testing
- Platelet Acetyl Coenzyme A Carboxylase analysis in CAD
- Where
- Belgium
- Volunteers
- 188 people, healthy volunteers welcome
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Lung Cancer
Sacituzumab Tirumotecan (Sac-TMT) Plus Bevacizumab in 3rd Generation EGFR-TKI Treated Advanced EGFR-mutant Nonsquamous NSCLC With Brain Metastasis
This is a prospective, single-center, phase 2 clinical study to explore the efficacy and safety of Sac-TMT in combination with bevacizumab for patients with EGFR-mutated nonsquamous NSCLC with brain metastases.
- Trial name
- NCT07197008
- Testing
- Sacituzumab tirumotecan (Sac-TMT) plus bevacizumab
- Volunteers
- 50 people
- Sponsor
- Li-kun Chen
Chronic Phase Chronic Myelogenous Leukemia, Accelerated Phase Chronic Myelogenous Leukemia
CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey
A multicenter, prospective cohort study of the mutation status of patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who are being treated with first or…
- Conditions
- Chronic Phase Chronic Myelogenous Leukemia, Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
- Trial name
- NCT03647215
- Where
- 33 sites in Ireland, United Kingdom
- Volunteers
- 427 people
- Sponsor
- Incyte Biosciences UK
NSCLC (Advanced Non-small Cell Lung Cancer), EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs
The goal of this prospective study is to explore the safety and preliminary efficacy of stereotactic body radiotherapy (SBRT) combined with ORIENT-31 regimen (Sintilimab plus bevacizumab plus platinum-doublet chemotherapy) for…
- Trial name
- NCT06775743
- Testing
- ORIENT-31 regimen, SBRT
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Fudan University
EGFR Activating Mutation, NSCLC Stage IV
Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC
This is a non-interventional, multi-center, ambispective cohort study in real world to describe the effectiveness and safety profile in patients with EGFR mutation-positive advanced NSCLC treated with dacomitinib (Vizimpro®) as…
- Conditions
- EGFR Activating Mutation, NSCLC Stage IV, NSCLC Stage IIIB, NSCLC, Recurrent
- Trial name
- NCT04768491
- Testing
- Dacomitinib
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Peking Union Medical College
Coronary Artery Disease
Evaluation of the GTX™ 5126 DES Coronary Stent System in the Treatment of Patients With a Lesion in the Coronary Artery
The GTX™ Drug Eluting Coronary Stent System is intended for the treatment of patients with a lesion in the coronary artery.
- Trial name
- NCT00777842
- Testing
- GTX™ Drug Eluting Coronary Stent System
- Where
- Germany
- Volunteers
- 19 people
- Sponsor
- Cook Group Incorporated
Hepatocellular Carcinoma, Colorectal Cancer
Prospective Clinical Validation of Next Generation Sequencing (NGS) and Patient-Derived Tumor Organoids (PDO) Guided Therapy in Patients With Advanced/ Inoperable Solid Tumors
Precision oncology aims to improve clinical outcome of patients by offering personalized treatment through identifying druggable genomic aberrations within their tumors.
- Trial name
- PDO (NCT06077591)
- Testing
- Patient-Derived Tumor Organoids
- Where
- Hong Kong
- Volunteers
- 40 people
- Sponsor
- Chinese University of Hong Kong
Pneumonia, Diagnosis
Metagenomic NGS for Diagnosis of Pneumonia
In this randomized controlled trial, we aim to evaluate the efficacy of incorporating mNGS in the management of pneumonia on efficiency and accuracy of causative pathogen identification, proportion of participants with effective…
- Trial name
- NCT05979350
- Testing
- Metagenomic next-generation sequencing, Standard work-up for pneumonia
- Where
- Taiwan
- Volunteers
- 114 people
- Sponsor
- National Taiwan University Hospital
Eye Diseases
Increasing Vision Center Service Utilization
Background: Vision Centre (primary eyecare facility): a major eye care service model catering to underserved rural areas. The sustainability of rural Vision Centres (VC) in north India is a major challenge due to the…
- Trial name
- NCT04800718
- Testing
- Intervention Arm
- Where
- India
- Volunteers
- 1,500 people
- Sponsor
- Seva Foundation
NSCLC (Non-small Cell Lung Cancer)
Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy
This study is a multicenter, single-arm, phase II clincial trial. The main objective of the study is to evaluate the efficacy and safety of the combination of Sacituzumab Tirumotecan (sac-TMT) and Furmonertinib in the treatment…
- Trial name
- NCT07193160
- Testing
- Sacituzumab Tirumotecan, Furmonertinib
- Volunteers
- 45 people
- Sponsor
- Fudan University
Severe Aplastic Anemia (SAA)
A Description of Bacteria in the Mouths of Patients With Severe Aplastic Anemia
Background: This research is being done to describe the types of bacteria found in the mouths of patients who have severe aplastic anemia (SAA) and are treated with drugs that suppress the immune system or with stem cell…
- Trial name
- NCT01900119
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Rare Diseases, Genetic Predisposition
Diagnostic Value of Exome/ Genome Sequencing, Conventional Methods in Rare Diseases and Familial Tumor Syndromes
For the retrospective data analysis, patients with genetic diseases of any age and, if available, other family members, for whom genetic analyzes were carried out between 10/2016 and 12/2020, should be included.
- Trial name
- EXGEFATU (NCT04731857)
- Testing
- Retrospective data analysis
- Where
- Germany
- Volunteers
- 12,000 people
- Sponsor
- University Hospital Tuebingen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.